BRIEF-Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

IONS

0.00

June 24 (Reuters) - Ionis Pharmaceuticals Inc IONS.O:

  • TRYNGOLZA® (OLEZARSEN) APPROVED BY THE FDA AS THE FIRST AND ONLY TREATMENT TO REDUCE TRIGLYCERIDES AND THE RISK OF ACUTE PANCREATITIS IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG)

  • IONIS PHARMACEUTICALS - TRYNGOLZA AVAILABLE IN 50 MG OR 80 MG DOSE, SELF-ADMINISTERED MONTHLY

  • IONIS PHARMACEUTICALS - TRYNGOLZA TO BE AVAILABLE IN U.S. FOR SHTG IN JULY

Source text: ID:nBw9X7BDLa

Further company coverage: IONS.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.